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Abstract
Uterine sarcomas (USs) account for 3–9% of uterine malignant neoplasia and about 5%
of all gynaecologic malignancies. Despite their low prevalence, these tumors stimulate
a great interest because of their aggressiveness, poor prognosis and high mortality
rate. According to the last World Health Organization (WHO) classification and the
International Federation of Gynecology and Obstetrics Committee (FIGO) staging,
USs are categorized as pure mesenchymal tumors (endometrial stromal sarcoma,
leiomyosarcoma and undifferentiated uterine), and mixed tumors (carcinosarcoma
and adenosarcoma). Due to their non-specific signs and symptoms, USs are com-
monly diagnosed in advanced stage, more often after surgery for a suspected
leiomyoma. Although surgery followed by adjuvant therapies represent the common
choices for USs, they show poor efficacy due to the early occurrence of metastasis, and
the high resistance of tumors to radio-and chemotherapy. Presently, specific expres-
sion profiles and new cytotoxic agents are under investigation. In these reviews, we
summarized clinical and pathological features, imaging characteristics, therapeutic
approaches, genomic and molecular aberration associated with smooth muscle neo-
plasia (Part 1) and endometrial stromal neoplasia (Part 2); the goal is to understand
the biology and the molecular signature of these tumors, in order to focus on their best
management.
Keywords: uterine sarcomas, mesenchymal tumors, uterine malignant neoplasia, uterine
smooth muscle neoplasia, leiyomiomas, STUMP
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction: why these chapters?
Cancers of the female reproductive system (cervix uteri, corpus uteri, vulva, vagina, ovaries
and fallopian tubes) are important causes of morbidity and mortality worldwide, accounting
for almost 15% of all female neoplasia [1].
Uterine cancer is defined as any invasive neoplasm of the uterine corpus and represents the
fourth most common malignancies in women, after breast, lung and colorectal cancer [2].
Uterine cancers originating from mesenchymal elements of the uterus are defined as uterine
sarcomas (USs). They are very rare, representing about 5% of all gynaecologic malignancies
and 3–9% of all uterine cancer [1, 2].
USs usually manifest in postmenopausal women. Obesity, diabetes mellitus, nulliparity and
hypertension, considered as certain risk factors for the development of endometrial carcinoma,
do not seem to have a crucial role in the genesis of USs [3]. Moreover, most authors reported a
three times risk for USs developing in patients undergoing prolonged use of tamoxifen, a
synthetic oestrogens (ERs) receptor agonist largely used in the management of women with
oestrogens receptor-positive breast cancer [3]. Tamoxifen-related US usually occurs about
5 years following tamoxifen therapy and presents with a higher stage of disease [3].
Because of the rarity of USs, their histopathological heterogeneity and aggressiveness, there is
a general lack of consensus regarding risk factors and treatment options [2].
The only certainty is that, if compared with the epithelial counterpart, uterine sarcoma is
associated with a poor prognosis, a high rate of local recurrence and distant metastasis [1].
In this chapter, we systematically focus on each single type of USs, starting from epidemiolog-
ical and etiological factors, going through clinical, morphological and molecular characteris-
tics, differential diagnosis and prognostic features, finally achieving conventional and novel
therapeutic approaches.
2. The mesenchyma
Mesenchyma consists of loosely packed and mobile cells embedded in a network of fibers and
fluid called intercellular matrix. Mesenchymal cells are spindle-shaped, with oval nucleus and
scant cytoplasm.
The loose nature of the mesenchymal cells allows them to easily migrate. Moreover, during
embryogenesis and foetal development, their pluripotent nature makes them able to differen-
tiate into a great variety of structures: bones, cartilage, teeth, blood cells, endothelial lining of
blood and lymphatic vessels, and smooth muscles.
Mesenchyme derives from mesoderm germ layer and forms early during embryogenesis.
Mesenchymal cells also derive from the neural crest, a specialized ectodermal structure. During
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gastrulation, mesenchymal cells lose their adhesiveness and separate from the connected
sheets of epithelial cells. This process is known as epithelial-mesenchymal transition (EMT).
Some important events take place during interactions between mesenchymal and epithelial
cells. Epithelial cells are often induced in changing their shape and arrangement in response to
signals originating from mesenchymal cells [4].
During EMS, epithelial cells lose their polarity. Cell membranes and desmosomes dissolution,
degeneration of cytocheratin filaments, increased cell resistance to apoptosis, and migration of
new epithelial cells with mesenchymal phenotype also occur [4]. These changes are induced by
the mechanical stimulation of migrating mesenchymal cells or by biochemical mechanisms [4].
EMT has to be considered as a physiological process, playing a role in the development of
various embryo tissues, as well as in cells proliferation and tissue repair. EMT is also essential in
driving folliculogenesis and ovulation [5]. It has been hypothesized that pathological process
such as adenomyosis, endometriosis, malignant neoplasia and metastasis would derive from the
dysfunction of EMTwithin the epithelial cells of the female reproductive system [6, 7].
EMT also participates in other pathological processes, including metastatization [8].
In cancer cell lines, cells gradually change from epithelial to spindle-like shape and acquire
fibroblastic morphology [4]. During this process, the expression of epithelial markers decreases
and the cells progressively acquire mesenchymal markers [4]. This mesenchymal signature
facilitates the detachment of tumor cells, the proteolytic digestion of basement membrane, the
vascular invasion, and the migration of circulating cells towards distant sites [8].
Little is still known about the detachment of circulating tumor cells from the cytoskeleton. It seems
that EMT produces detyrosinated α-tubulin with the formation of microtubules-basedmembrane
protrusions, which are distinct from the actin-based prolongations known as lamellipodia and
filopodia. The new acquired protrusions make circulating tumor cells with mesenchymal pheno-
type able to attach to endothelial layers and to migrate towards distant sites [9].
Three types of EMT have been described. EMT type 1 plays an important role in the organogen-
esis; it also generates the primitive mesenchyma during embryogenesis. EMT type 2 is charac-
teristic of pathological, non-neoplastic processes. Through EMT2, fibroblasts are recruited to
repair tissue; EMT2 also causes fibrosis as a consequence of chronic inflammations (i.e. renal
and hepatic fibrosis, Crohn’s disease). It has been demonstrated that about one-third of the
fibroblasts causing chronic glomerulonephritis, diabetic nephropathy, lupus nephritis and Alport
syndrome occurring during renal fibrosis originates from tubular epithelial cells. They are
recruited because of the damage of basement membrane. EMT type 3 allows tumor cells to
dissociate, migrate and metastasize [9].
EMT is regulated by transcriptional and post-transcriptional mechanisms, particularly through
downregulation of E-cadherin and overexpression of mesenchymal proteins such as vimentin
and N-cadherin [9].
If mesenchymal cells would have a crucial role duringmorphogenesis, they often remain undiffer-
entiated in adults. Undifferentiated mesenchymal cells, known as stem cells, exist in small
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quantities in bone marrow, fat, muscles and in dental pulp of baby teeth. They retain the ability to
differentiate into different kind of connective tissues for reparative or regenerative reasons [9].
Mesenchymal-epithelial transition (MET) is the reverse process by which mesenchymal cells
acquire adhesive properties and arrange themselves into organized sheets. MET would also
need to generate the so-called ‘secondary epithelium’ in various organs (i.e. kidney) [6]. When
required, the secondary epithelium can re-differentiate towards mesenchymal tissues by medi-
ation of several genes [6]. The switch EMT-METwould also induce neoplastic cells in acquiring
a stem cell pattern. This pattern helps to prevent apoptosis and senescence, and would contrib-
ute to both immunosuppression and multidrug resistance [6]. These converted mesenchymal
cells are not able to migrate toward the blood flow and cause local recurrence. In metastatic
sites, in accordance with local microenvironment, an EMT-MET switch would occur. Restora-
tion of epithelial features allows cells to arrange in clusters contributing to the stability of the
metastatic focus.
3. Uterine sarcomas: the history
Sarcomas are malignant neoplasia occurring in any site of the body in which mesenchymal
tissues are present. Because of their mesodermal origin, sarcomas are characterized by histolog-
ical and cytogenetic heterogeneity. The histological classification of sarcomas is made according
to tissue differentiation [1].
Homologous USs refer to mesenchymal tissues, which are normally found in the uterus, such as
smooth muscle, endometrial stroma, vascular and fibrous tissue. Heterologous USs refer to
mesenchymal tissues that are foreign to the uterus, such as cartilage, bone, skeletal muscle and fat.
In the past, sarcomas originating from different organs were grouped together; such classifica-
tion demonstrated a scant utility from a clinical point of view [1]. Recently, basing on cells
differentiation and growth pattern, the World Health Organization (WHO) proposed a sepa-
rate histological classification for uterine neoplasia. Thus, uterine mesenchymal neoplasias
were grouped as smooth muscle tumors and endometrial stromal tumors [10]. Uterine smooth
muscle tumors are defined as benign and malignant neoplasms arising in the context of
myometrium and composed of cells showing smooth muscle differentiation. Among these,
benign leiomyoma, smooth muscle tumor of uncertain malignant potential (STUMP) and
leiomyosarcoma (LMS) are listed [10].
Endometrial stromal tumors enclose all the neoplasia originating from the uterine endometrial
stroma: endometrial stromal nodule (ESN), endometrial stromal sarcoma (ESS) and undiffer-
entiated uterine sarcoma (UUS) [10] (Figure 1).
Nowadays, being carcinosarcoma (CS) considered as a dedifferentiated/metaplastic form of
endometrial carcinoma, together with Müllerian adenosarcoma (MA), it is encompassed among
the ‘mixed epithelial and mesenchymal tumours’ [11].
Tumor stage represents the most important prognostic factor for USs. In the past, USs were
inadequately staged using the same 1988 staging system utilized for endometrial carcinoma.
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In 2009, a new International Federation of Gynecology and Obstetrics Committee (FIGO) staging
system was specifically developed [12]. It comprises two sections, one for both leiomyosarcomas
and endometrial stromal sarcomas and another for the adenosarcomas. The staging system used
for carcinosarcomas is the same used for endometrial carcinomas.
4. The two great excluded
Müllerian adenosarcomas (MAs) account for 5.5–9% of all USs [1]. They are commonly seen in
postmenopausal women, even if cases occurring in adolescents and young women are
described. MA typically shows benign epithelial cells together with homologous/heterologous
mesenchymal sarcomatous components. Neoplasia is often limited to the endometrium, since
myometrial invasion is extremely rare. Malignant potential is low as well as histological grade
at fist presentation [1]. The 5-year survival rate for stage I is of about 76% [1]. MAs are
polypoid in shape and may contain small internal cysts. Tumor cell necrosis, if present,
represents the most important prognostic factor [1].
Carcinosarcoma (CS), also known as malignant mixed Müllerian tumor (MMMT), has been
recently considered as a metaplastic carcinomas basing on a different derivation from a com-
mon monoclonal stem cell [13]. Clinical, pathological and molecular evidences would confirm
the monoclonal origin of carcinosarcomas, which would further undergo both epithelial and
mesenchymal differentiation during its development [13]. For other authors, a CS would
Figure 1. 2014 WHO classification of uterine sarcomas.
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originate from a carcinoma undergoing sarcomatous metaplasia through a dedifferentiation
process [14].
The peculiar molecular features of CSs, as well as their good response to adjuvant therapies,
would confirm the epithelial derivation of these tumors which characteristically shows a high
aggressiveness and a high frequency of lymph nodal and distant metastases. Thus, the prog-
nosis of CS would depend on the carcinomatous component [15].
Noticeably, patients with MA and CS tend to be much older than patients bearing US [15].
5. Leiomyosarcoma
After the exclusion of CSs, leiomyosarcomas (LMSs) represent the most commonUSs (30%), being
the endometrial stromal sarcomas the second (10–15%). Rhabdomyosarcoma, angiosarcoma and
liposarcoma are extremely rare [1].
LMSs develop in the smooth muscle layer of the uterus, called myometrium; thus, malignant
cells show smooth muscle differentiation.
5.1. Epidemiology
The worldwide annual occurrence rate of USs is 1.55–1.95 per 100,000 women. The peak of
incidence is in the fifth decade (50–55 years), about 10 years later than leiomyoma. In younger
women, the incidence of LMS strictly correlates with the use of tamoxifen in adjuvant breast
cancer therapy [16].
The percentage of incidental LMS among women undergoing surgery for suspected leiomyoma
increases with age, being about 0.2% in patients aging 31–40, 0.9% among those aging 41–
50 years of age, about 1.4% in women aging 51–60 and 1.7% in patients ranging from 61 to
81 years of age [15].
LMS is most common in black race. The relative risk and incidence of both leiomyomas and
LMS is two- to threefold greater in black women than in white ones [1].
5.2. Aetiology
The risk factors for LMS are still unknown. The role of obesity, nulliparity, hypertension and
diabetes mellitus, recognized as influencing the development of other uterine malignancies, are
uncertain yet. On the other hand, some evidences demonstrated that the use of tamoxifen for
5 years or more is associated with an increased relative risk of developing an LMS, although the
absolute risk remains low [15]. Pelvic irradiation, a history of retinoblastoma in childhood,
hereditary leiomyomatosis and renal cell carcinoma are other documented risk factors [15].
Finally, although it is now clear that the vast majority of LMSs arise independently, it is now
accepted that a small percentage would derive from the transformation of a pre-existing
leiomyomas [17].
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5.3. Clinical features
Since pelvic examination cannot distinguish between leiomyoma and LMS, the pre-surgical
differential diagnosis is very difficult. In both cases, symptoms are not specific. Patients often
present with vaginal bleeding or discharge, lower abdominal mass and pelvic pain. Size,
contour and mobility of the uterus along with any other possible findings (i.e. cervical abnor-
malities or vaginal nodules) should be evaluated during gynecological examination. A fixed
mass is commonly suggestive of a malignant neoplasm, even if a malignant neoplasm not
infiltrating the uterine serosa is often mobile. A rapidly growing solitary intramural or sub-
serosal uterine mass should be suspected for an LMS, especially in the absence of hormonal
stimulation or in non-pregnant women. LMS shows lymph nodal or haematogenous spreads.
Lung represents the preferential site for distant metastasis. When local metastases occur,
gastrointestinal or urinary symptoms may be associated [1].
5.4. Imaging
Imaging features for LMS are similar to those of leiomyoma.
At transvaginal ultrasound examination, LMS shows echogenic components mixed with
anechoic areas due to necrosis. Color Doppler usually demonstrates irregular vessel distribution
and low impedance to flow. All of these characteristics may also be found in leiomyomas [18].
Computed tomography (CT) is not able to differentiate between leiomyomas and LMS. A
specific characteristic of LMS would be the absence of calcifications, which are usually seen in
leiomyomas outgrowing their blood supply [19].
Magnetic resonance imaging (MRI) has been reported to have high sensitivity in LMS diagno-
sis, although specificity is low [19]. Contrast-enhanced MRI (CE-MRI) demonstrates signifi-
cantly higher accuracy and specificity if compared with diffusion-weighted MRI (DW-MRI),
while sensitivities are comparable [19].
Finally, even if the uptake of fluorodeoxyglucose (FDG) in positron emission tomography/CT
(PET-CT) is usually high in LMS and low in leiomyomas, the use of this technique in differen-
tial diagnosis is limited, since leiomyomas can uptake FDG too [20].
In conclusion, although most studies demonstrated that pelvic ultrasound followed by MRI
represents the most useful strategy in LMS diagnosis, the vast majority of the authors con-
cluded that no pelvic imaging is able to reliably differentiate between LMS and leiomyomas.
5.5. Surgical specimens
LMS is commonly diagnosed after surgery for a suspected leiomyoma [1, 16, 19].
Although fine needle biopsy and curettage samples have been proposed as good diagnostic spec-
imens, their use is limited. In the context of an LMS, areas showing histological features indistin-
guishable from those of leiomyoma may be seen. For this reason, histological diagnosis requires
the evaluation of the entire neoplastic mass, obtained by myomectomy or hysterectomy [21].
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In addition, since the distribution of atypia and mitosis is not homogeneous in the context of a
malignant mesenchymal mass, an accurate estimation requires extensive sampling.
Intra-operative diagnosis on frozen section demonstrated to be limited too, although this tech-
nique remains essential to drive the extension of the surgery [21]. Hysterectomy may be
performed by laparotomy or laparoscopy. Using laparotomy, the specimen is not morcellated.
By laparoscopy, only the suspected mass is removed; in such cases, the specimen is morcellated
and might favor dissemination of malignant cells within the peritoneal cavity [22]. Occasionally,
smooth muscle cells have been found in pelvic washing after laparoscopic myomectomy [22].
5.6. Pathological findings
5.6.1. Macroscopic features
About 65% of LMSs are intramural, 20% are submucosal, 10% are subserosal and 5% originate
from cervix. Characteristically, LMS presents as a large solitary mass, although the develop-
ment of an LMS in a uterus harboring multiple leiomyomas is common [1]. Usually, LMS
presents as a voluminous mass with a mean diameter of 10 cm. Its margins are often well
defined, although focal infiltration of the adjacent myometrium may also be seen. Irregular
margins and lacking of a clear line of demarcation separating LMS from normal myometrium
usually indicate invasive behaviour. Because of the possible overlap in shape between LMS
and ischemic degeneration of leiomyoma, most of smooth muscle neoplasms suspected to be
malignant at imaging are found to be benign at microscopic evaluation [23]. Grossly, LMS is
very different from leiomyoma, the former revealing a fleshy consistency, a bulging cut surface
and a pearly white-to-gray color; necrotic and haemorrhagic foci are often seen. The typical
whorled appearance of leiomyoma is always lacking. The presence of hemorrhage and necro-
sis should always be regarded as suspected for LMS. When cystic changes are present, samples
should be mainly taken on the solid areas [1].
5.6.2. Microscopic features
LMS is composed of connected bundle cells showing smooth muscle differentiation. Nuclei are
round with one or more prominent nucleoli. Multinucleated giant cells with osteoclast-like
shape may be present (Figure 2A) [24]. The three cardinal microscopic features characteristics
of LMS are tumor cell necrosis (Figure 2B), nuclear atypia (Figure 2C) and mitotic count >10/10
High Power Fields (HPFs) (Table 1). Even if all of these three cardinal features are usually
detected in about 80% of typical LMS, the presence of two of three is sufficient to reach the
diagnosis [1].
Three types of necrosis have been described in smooth muscle tumors: (1) ulceration with
submucosal necrosis; (2) infarct-type necrosis, encountered in both benign and malignant neo-
plasms and (3) tumor cell necrosis, characterized by distinct and harshly demarcated necrotic
zones, suddenly transiting towards non-necrotic zone [1, 26]. Tumor cell necrosis is specific for
LMS and should also be distinguished from hyaline or degenerative necrosis, which can be
seen in both leiomyomas and other types of sarcomas (Table 2) [26].
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If infarct-type necrosis is present, it should be evaluated in conjunction with nuclear atypia and
mitoses (Figure 2D), since it is common in both benign and malignant neoplasms [1, 16].
Other features that should be included in the pathological assessment of uterine LMS are
tumor size, presence of vascular invasion (Figure 2E, F), occurring in 10–27% of the cases, and
status of surgical margins [26]. Hypercellularity does not discriminate between LMS and
leiomyoma [1]. As previously shown, the specimen should be adequate to exactly evaluate
the mitotic rate. To obtain adequacy is essential to analyze one section every 1–2 cm of tumor
diameter, to count mitotic figures only in mitotically active areas at 60 magnification, and to
evaluate five sets of 10 consecutive HPF, excluding degenerating cells [1]. Some drugs and
hormones may induce histological changes mimicking necrosis; for example, iatrogenic cell
necrosis in a histological background of atypical leiomyoma could lead to a wrong diagnosis of
LMS. For this reason, pathologists should be informed of any therapies [1, 26]. A tumor lacking
coagulative cell necrosis and nuclear atypia should be diagnosed as mitotically active
leiomyoma in the presence of 5–20 mitoses/10 HPF, or as Stromal Tumor of Undetermined
Malignant Potential (STUMP) when mitotic count is >20 mitoses/10 HPF. A tumor lacking
coagulative necrosis but showing diffuse moderate–severe nuclear atypia should be consid-
ered as atypical leiomyoma when mitosis is <2/10 HPF, as STUMP when mitotic count is 2–10/
Figure 2. Uterine leiomyosarcoma. (A) Bundles of cells with smooth muscle differentiation, and multinucleated giant
cells with osteoclastic shape (arrow), Ematoxilin-eosin (EE), 20x. (B) Tumor cell necrosis: Demarcated necrotic zones
abruptly transiting towards non-necrotic zone; EE, 10x. (C) Nuclear atypia (circle), EE, 40x. (D) Mitosis (square), EE, 60x.
(E) Vascular invasion with artery embolization, EE, 10x.(F) The wall of the vessel shows CD31 positivity, 10x. (G) Desmin
positive stain in neoplastic cells, 10x.
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10 HPF, as LMS when mitoses are more than 10/10 HPF. A neoplasia showing coagulative
necrosis without a significant nuclear atypia should be classified as STUMP when mitosis is
less than 10/10 HPF, as LMS when at least 10 mitoses/10 HPFs are found. Finally, a tumor with
coagulative necrosis and significant nuclear atypia, regardless of mitotic count, should be
diagnosed as LMS [1].
In the past, Broder’s classification was one of the most used systems to grade LMS. It consid-
ered four categories: grade 1, mild cytological atypia; grade 2, more nuclear irregularity; grade
3, intermediate between grades 2 and 4; grade 4, the presence of bizarre cells. [27]. Other
authors classified LMS basing on the level of differentiation (well, moderately and poorly
Tumor cell necrosis Atypia Mitosis/10 HPFs Diagnosis
Present Diffuse, moderate–severe Any Leiomyosarcoma
None-mild
≥10 Leiomyosarcoma
<10 Leiomyosarcoma
Absent Diffuse, moderate–severe
≥10 Leiomyosarcoma
<10 Atypical leiomyoma
None-mild
≥10 Leiomyoma
<10 Mitotically active leiomyoma
Focal, moderate–severe
<10 Leiomyoma with limited experience
≤10 STUMP
HPF, high power fields; STUMP, smooth muscle tumor with uncertain malignant potential. (Modified from Ref. [25]).
Table 1. Diagnostic criteria for smooth muscle tumors.
Coagulative tumor cell necrosis Hyalinizing necrosis
Common in malignant smooth muscle tumors Common in leiomyomas
Sudden transition to vital to necrotic areas Area of fibrous and granulation tissue between vital and necrotic areas
Necrotic cells look ghostly No cell shadows are visible
Rare inflammation Presence of immune complexes
Abrupt borders Slight borders
Blood vessels are not involved Blood vessels are involved by fibrin deposits; their walls are thickened
Hyperchromatic and atypical nuclei Pale nuclei
Table 2. Types and characteristics of necrosis in smooth muscle tumors.
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differentiated) [28]. A binary categorization into low- and high-grade categories was rarely
used, since it has been demonstrated that it is quite impossible to recognize a low-grade
uterine LMS at the time of diagnosis [28]. Presently, according to WHO, no grading should be
performed for LMS [1].
5.6.3. Immunohistochemistry
Although immunohistochemistry (IHC) does not represent a necessary tool in LMS diagnosis,
it may help in distinguishing LMS from other uterine malignancies (Table 3).
Desmin, h-caldesmon, smooth muscle actin and histone deacetylase 8 (HDAC8), the so-called
smooth muscle markers, are usually expressed in LMS (Figure 2G), even if immunoreaction
Antibody
markers
Typical LMS Epithelioid LMS Myxoid LMS STUMP
Smooth muscle
actin
+  +
Desmin +  
h-cardesmon +  
EMA +, patchy + +, patchy
CD10 +, patchy +, patchy +, patchy
CD34 — — —
CD44 — — —
Cytokeratins +, patchy + —
HDAC8 + + +
ER if +, better prognosis if +, better prognosis if +, better prognosis 
PR if +, better prognosis if +, better prognosis if +, better prognosis 
p53    
p21 if +, poor prognosis if +, poor prognosis if +, poor prognosis +
Bcl-2 if +, better prognosis if +, better prognosis if +, better prognosis if +, good prognosis
MIB1 poor prognosis for high
percentage
poor prognosis for high
percentage
poor prognosis for high
percentage
Absent or low
percentage
p16 if +, high risk of relapse if +, high risk of relapse if +, high risk of relapse 
Inhibin — — —
S100 may be + — may be +
c-kit  —  
Cyclin D1
LMS, leiomyosarcoma; STUMP, smooth muscle tumors of uncertain malignant potential.
Table 3. Immunohistochemical features of uterine smooth muscle neoplasia.
Uterine Sarcomas: An Updated Overview. Part 1: Smooth Muscle Tumors
http://dx.doi.org/10.5772/intechopen.76772
37
for one or more of these markers (particularly for desmin and h-caldesmon) can be lost or may
be weak in some LMS variants, such as myxoid and epithelioid ones [29]. LMS is generally
negative of focally positive for CD10, but it is still unknown whether CD10-positive foci have
to be considered as areas of endometrial stromal differentiation within smooth muscle neo-
plasms [30].
LMS does not immunoreact with CD44, whereas leiomyoma and normal myometrium express
this marker [1]. CD44 demonstrated sensitivity, specificity, and positive- and negative-predictive
values near to 100%; thus, it is very useful in problematic cases [29]. Epithelial markers such as
cytokeratins (CKs) and epithelial membrane antigen (EMA) may also be expressed in LMS,
although their expression is weak and focal [29]. Focal positivity for CAM5.2 may also be seen.
Expression of estrogen (ER) and progesterone (PR) receptors has been reported in 57 and 43%
of LMS cases, respectively; the corresponding percentage for leiomyoma is 78 and 88% [31]. In
general, LMSs staining positive for ER and PR demonstrated to be less aggressive than the
negative counterpart [31]. Positivity for c-kit may also be seen, although a variable proportion
of LMS without c-kit mutation has been identified [1]. The percentage of MIB1-positive cells is
usually high in LMS, if compared with leiomyomas. p53 positivity is detected in about 50% of
LMS but not in leiomyoma [32]; tumors overexpressing p53 are more aggressive than those
showing p53 negativity [32].
p16 antibody seems to be useful in distinguishing between benign and malignant uterine
smooth muscle neoplasia. In particular, a strong and diffuse p16 positivity associated with
p53 positivity would favor an LMS diagnosis. In addition, p16 expression seems to be strictly
related to a highest risk of LMS relapse [33].
5.7. Histological variants of LMS
Several histological subtypes of LMS have been recognized, although it is unknown if this
classification may have a clinical relevance.
Usual leiomyosarcoma is composed of fascicles of spindle-shaped cells with eosinophilic cyto-
plasm, resembling the normal myometrial smooth muscle.
A tumor lacking all the three main cardinal histological features seen for LMS should be
diagnosed as leiomyoma (Figure 3); a tumor showing one of three main features should be
categorized as atypical leiomyoma or STUMP [1].
Myxoid leiomyosarcoma is the less common variant. Grossly, it appears as a well-circumscribed,
voluminous and gelatinous mass. Commonly, myxoid change is seen in about 30% of the
tumor mass. Histologically, it differs from the classic form of LMS due to hypocellularity and
myxoid stroma. A significant cytological atypia and a high mitotic activity are usually lacking
[34]. Within myxoid areas, no more than 2 mitosis/10 HPFs are often seen, although a higher
mitosis number may be present in the context of smooth muscle fascicles. Smooth muscle cells
stain positive for smooth muscle markers (Table 3). Myxoid LMS usually shows clinically
malignancy, since it is highly infiltrative [1].
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Epithelioid leiomyosarcoma is characterized by the presence of round-polygonal smooth muscle
cells with abundant eosinophilic cytoplasm and round nuclei, arranged in nests, cords or
plexiform patterns. The clinical behaviour of epithelioid tumors with a moderate mitotic
activity (2–4 mitosis/10 HPFs) is not well understood. About 10% of epithelioid LMS larger
than 6 cm recurred or metastasized [1]. These cases are classified as STUMP and need a careful
follow-up [34].
Leiomyosarcoma with osteoclastic giant cells is a rare but more aggressive variant of LMS [1]. The
background is similar to those of typical LMS; however, histiocytic CD68-positive cells may be
detected admixed with smooth muscle cells staining positive for smooth muscle cell markers.
Overall survival is <2 years after presentation, even with radiation or chemotherapy1 [1].
In xanthomatous LMS, smooth muscle cells show microvesicular and foamy cytoplasm.
The three cardinal features used to diagnose typical LMS are often hard to assess in epithelioid
and myxoid variants [35]. In patients showing a worse prognosis, two or more of the following
features are usually detected: tumor size of 5 cm or more, infiltration of the adjacent tissues,
cytological atypia, high mitotic index, necrosis and lymph vascular invasion [35]. Particularly,
cut-off values of 10 mitoses/10 HPFs, ≥4 mitoses/10 HPFs and ≥2 mitoses/10 HPFs are used for
typical, epithelioid and myxoid LMS, respectively [16].
5.8. The 2009-revised FIGO staging system for LMS
Staging of LMSs is very important to drive treatment. The International Federation of Gyne-
cology and Obstetrics Committee (FIGO) recognized that the old classification was no longer
sufficient and that USs require an independent staging [35]. The old staging system looked at
how far the cancer spreads; FIGO staging, essentially being a post-surgical staging, relies on
histological examination.
Moreover, while FIGO staging is more precise in detecting tumors with a worse prognosis,
staging by the American Joint Commission on Cancer (AJCC) demonstrates to be more
Figure 3. Typical leiomyoma. EE, 10x.
Uterine Sarcomas: An Updated Overview. Part 1: Smooth Muscle Tumors
http://dx.doi.org/10.5772/intechopen.76772
39
accurate in identifying patients with a good prognosis (Table 4). In general, neither the former
nor the latest are able to provide an exact estimation of the overall survival for LMSs [36].
5.9. Diagnostic problems with LMS
Among uterine sarcomas, LMS represents a source of differential diagnostic problems, partic-
ularly with leiomyomas variants, which most often show macroscopic and histological fea-
tures causing misdiagnosis [1]. This fact would be essentially due to the hormonal uterine
milieu that would cause a high mitotic activity. A diagnosis of LMS would also signify a
challenge for clinicians, because of problems with its management. As previously shown,
among women undergoing hysterectomy or myomectomy for a myometrial mass, the preva-
lence of LMS is approximately 0.20% [37]. Thus, differential diagnosis between LMS and
leiomyoma is the first step to move when a uterine mass is suspected. Since the risk of compli-
cations during hysterectomy exceeds the risk of incidental LMS, women with a suspected
leiomyoma should be treated with a uterine-sparing surgical option [37]. Some conditions, which
may be considered as associated with LMS, but not with leiomyoma, include older age and
postmenopausal status. Being leiomyoma responsive to estrogen and progesterone, it frequently
arises during reproductive age (below 20 years of age in black women, and between 30 and 40s
in white women), while usually stabilizes or decreases in size in postmenopausal patients [37].
Basing on these considerations, a new or growing uterine mass in women above 40 years of age
should be suspected for LMS, while the level of suspicion for malignancies may be lower in
postmenopausal women undergoing oestrogens therapy [38]. Younger age cannot exclude a
FIGO stage Definition TNM Stage
I Tumor limited to uterus T1, N0, M0
IA <5 cm T1a, N0, M0
IB >5 cm T1b, N0, M0
II Tumor extended to the pelvis T2, N0, M0
IIA Adnexal involvement T2a, N0, M0
IIB Tumor extends to extra -uterine pelvic tissue T2b, N0, M0
III Tumor invades abdominal tissues (not just protruding into the abdomen) Any of the
following
IIIA One site T3a, N0, M0
IIIB More than one site T3b, N0, M0
IIIC Metastasis to pelvic and/or para-aortic lymph nodes T1-T3, N1, M0
IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases
IVA Tumor invades bladder and/or bowel mucosa T4, any N, M0
IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes any T, any N, M1
FIGO, International Federation of Gynecology and Obstetrics Committee; AJCC, American Joint Commission on Cancer.
Table 4. 2009-revised FIGO and AJCC (TNM) staging system for leiomyosarcomas.
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diagnosis of LMS. On the other hand, a rapidly growing large uterine mass cannot unequivo-
cally be associated to an LMS [38]. For all these reasons, histological examination represents the
milestone to distinguish between leiomyoma and LMS.
Recent data reported an increased risk of undetected LMS among postmenopausal patients
who underwent morcellation of uterine tissue [39]. Uterine sarcoma usually spreads via intra-
abdominal, lymphatic or haematogenous routes. It is worth noting that some histological
variants of leiomyomas may also disseminate. Thus, a careful diagnosis has to be done in the
presence of a widespread disease. Failure of medical treatment with gonadotropin-releasing
hormone agonist, or unsuccessful non-excisional procedures for a leiomyoma (such as uterine
artery embolization), has been reported in some LMS cases [39].
Genetic studies demonstrated that, in a vast majority of cases, an LMS does not originate from
a benign leiomyoma. LMS typically shows polyploidy and aneuploidy, while leiomyoma
displays genetic rearrangements which are often shared by other benign neoplasms. On the
other side, rare cases of leiomyoma progressing to LMS have been described [40]. In the
absence of risk factors, the vast majority of the authors agree to manage women for a
leiomyoma unless new symptoms develop. Conversely, a suspect of LMS should be put if
women failing response to medical therapy or when new symptoms appear.
5.10. Differential diagnosis
5.10.1. LMS versus intravascular leiomyomatosis, benign metastasizing leiomyoma, disseminated
pelvic leiomyomatosis
Intravascular growth, metastasis and pelvic dissemination are not included among the cardi-
nal features driving LMS diagnosis. Thus, they cannot be used to distinguish an LMS from a
leiomyoma. However, intravascular leiomyomatosis, benign metastasizing leiomyoma and
disseminated pelvic leiomyomatosis do not show significant cytological atypia, tumor cell
necrosis or a high mitotic count [1]. Recent findings demonstrated a distinctive genetic profile
in benign metastasizing leiomyomas [41].
5.10.2. LMS versus endometrial stromal sarcoma with smooth muscle differentiation
In endometrial stromal sarcoma with smooth muscle differentiation, smooth muscle cells do
not show necrosis or a significant mitotic activity. Moreover, these malignancies always con-
tain an endometrial stroma usually lacking in LMS [1].
5.10.3. Epithelioid LMS versus poorly differentiated carcinoma
A diagnosis of carcinoma is favored when malignant cells are associated with endometrial
hyperplasia. This diagnosis was also supported when neoplastic cells show positivity for
keratin and negativity for desmin and h-caldesmon (Table 3) [1]. When a distinction is impos-
sible to make, a diagnosis of ‘undifferentiated malignant neoplasm’ should be put. Electron
microscopic examination may sometimes help.
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5.10.4. LMS versus gastrointestinal stromal tumor (GIST)
Occasionally, GIST extends from the bowel wall simulating a fibroid. In such cases, differential
diagnosis between GIST and leiomyoma may be problematic since both tumors show spindled
cells without cytological atypia or mitotic activity.
Unlike LMS, GIST frequently shows spindle cells with cytoplasmic vacuoles, while the typical
fascicular architecture of muscle cells is lacking. Desmin expression in GIST is rare, while both
c-kit and CD34 expression are common. Basing on these evidences, the use of a panel includ-
ing desmin, c-kit and CD34 may be helpful in differential diagnosis [36].
5.10.5. LMS versus undifferentiated uterine sarcoma
Recent data demonstrated that there are no universal histological criteria able to distinguish
these two malignancies. In truth, it is also uncertain if there are significant clinical and thera-
peutic differences between them [36].
5.11. Molecular features
The oncogenic mechanisms leading to LMS remain unknown, even if the accumulation of
multiple genetic events has been demonstrated. In general, the number of molecular features
characteristic for LMSs is smaller if compared with those of endometrial stromal sarcomas.
Single nucleotide polymorphisms technique, gene expression arrays and DNA methylation
analyses show genomic modifications and mosaicisms in LMS; cytogenetic analyses also dem-
onstrated numerical and structural chromosomal abnormalities [42]. On the other hand, no or
limited genomic aberrations have been found in leiomyomas [42]. Thus, genomic instability
represents the hallmark of uterine smooth muscle malignancies [43]. The most frequent genomic
lost found in LMS involves 10q, 11q, 13q and 2p chromosomal arms. Particularly, the loss of
genetic material at chromosomal arms 1p, 14q, and 22q seems to be the same for both uterine
LMS and gastrointestinal stromal tumors (GISTs) [43]. The most common genomic gains in LMS
are Xp, 1q, 5p, 8q and 17p.91 [33]. Loss of heterozygosity (LOH) for long arm of chromosome 10
was found in about 50% of LMSs, but not in leiomyomas [43]. t(12;14)(q15;q23-24) translocation
has been detected in a high proportion of leiomyomas but not in LMS [43]. Some LMSs demon-
strated some types of X chromosome inactivation differing from those of leiomyomas. This fact
would confirm the theory of the independent transformation processes occurring in LMS and
leiomyoma [43]. Moreover, convincing evidences regarding the malignant transformation of
certain type of leiomyomas, such as the bizarre variant, are still lacking. LMS also shows a
significant higher frequency of allelic loss (FAL), if compared with leiomyoma (52 vs. 18%,
respectively) [44]. All these findings would support the hypothesis that the pathways for LMS
and leiomyoma are different [43]. Genetic instability would be the key to acquire sequential
genetic changes and mutations. Although the vast majority of USs are sporadic, some germline
mutations (i.e. mutation occurring in fumarate hydratase) are regarded as genetic risk factors for
the development of both LMSs and leiomyomas [45]. Most authors put their attention on the
mutations occurring in the gene named mediator complex subunit 12 (MED12), located at locus
Xq13.1 [46]. MED12 protein complexes with MED13, CDK8 and cyclin D [46]. Mutations of Exon
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2 in MED12 gene have been found in 70% of leiomyomas, particularly in the typical and
mitotically active variants [46]. For this reason, MED12 mutation cannot be used to determine
the behaviour of a smooth muscle neoplasia. The unique role of this marker would rely on the
individuation of the smooth muscle differentiation within a mesenchymal neoplasia [46].
Overexpression of high-mobility group AT-hook 2 (HMGA2) protein, frequently mutated in
uterine leiomyomas, seems to be inversely related to the presence of MED12 mutations [47].
By FISH analysis, TP53 mutations and PTEN deletions were detected in LMS, atypical
leiomyoma and STUMP [34]. A high expression of topoisomerase 2A (TOP2A) has been
found in a vast majority of LMSs, while low expression was seen in leiomyoma variants
and STUMP [48]. Expression of Stathmin1 activating the phosphoinositide-3-kinase (PI3K)
pathway was demonstrated to be significantly higher in LMSs, if compared with other
uterine smooth muscle tumors. Thus, the absence of Stathmin1 would not support a diagno-
sis of LMS [49]. Being the expression of the mRNA-binding protein IMP3 higher in LMS than
in benign smooth muscle neoplasia, it must be considered as a useful tool in differential
diagnosis [50]. CDC7, CDC20, GTSE1, CCNA2, CCNB1, and CCNB2 are overexpressed in
LMS, while K-ras is overexpressed in a small percentage of leiomyomas but not in LMSs [42].
MDM-2 oncogene negatively regulates apoptosis by (1) targeting p53 for ubiquitin-based
degradation, (2) blocking p53 transcriptional activation domain and (3) shuttling p53 from
the nucleus to the cytoplasm [42]. Amplification of MDM-2 has been reported in 10% of
uterine LMS and in extra-uterine LMS, but not in leiomyomas [42]. The block of MDM-2
would enhance p53 function, thus providing a targeted therapeutic strategy. Abnormalities
of the retinoblastoma-cyclin D pathway have been found in about 90% of LMSs [42]. All the
above mentioned aberrant molecular patterns, the vast majority of which is different for
LMSs and leiomyomas, confirm the different nature of these tumors. Cell cycle markers and
proliferation proteins (p16, p21, p27, p53, PCNA, Ki-67 and PHH3) are presently under
consideration. p16INK4a has been found to be implicated in the genesis of LMS [51]. p16
binds to cyclin D/CDK4 complex regulating cell cycle through G1/S progression. p16-/
CDK4A would act as a negative cell cycle regulator, by blocking cell cycle progression of
neoplastic cells and accelerating cell senescence. Ki67 antigens identify both normal and
neoplastic cells under proliferation. Recently, statistically significant higher level of both
PCNA and Ki67 has been found in uterine LMSs in comparison with leiomyomas. The
percentage of MIB1-positive cells would help to predict LMS prognosis and neoplastic
spread [1].
In conclusion, among the several markers listed above, TOP2A, IMP3, Stathmin1, HMGA2 and
MED12 are demonstrated to be promising in distinguishing between LMS and leiomyoma.
Most studies recently focused on molecular markers able to predict progression risk and
prognosis of a LMS. Slatter et al. correlated the presence of ALT and PML bodies (APBs) to a
poor prognosis of LMS [52]. Next-generation sequencing confirmed the presence of ATRX
mutations in LMS and their association with a poor survival [53]. RNA sequencing identified
three distinct molecular subtypes of LMS; subtype II was demonstrated to have the worse
prognosis [54]. Leiomodin (LMOD1) and ADP-ribosylation factor-like 4 C (ARL4 C) are now
considered as specific markers for LMS types I and II [54]. The expression of progesterone
receptor has been recently included in FIGO staging as an independent prognostic factor for
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stage I LMS [2]. On the other hand, overexpression of c-myc proto-oncogene does not correlate
with smooth muscle tumor prognosis, since it has been detected in about 50% of both
leiomyomas and LMSs [2].
Gene expression profiling individuated 203 probes, which were differentially expressed in pri-
mary and metastatic LMSs. Among these, OSTN, NLGN4X, NLGN1, SLITRK4, MASP1, XRN2,
ASS1, RORB, HRASLS and TSPAN7 were overexpressed in primary LMSs, while TNNT1,
FOLR3, TDO2, CRYM, GJA1, TSPAN10, THBS1, SGK1, SHMT1, EGR2 and AGT were
overexpressed in metastatic LMSs [55]. By flow cytometry, about 70% of LMSs showed aneu-
ploidy; thus, DNA ploidy may probably help in identifying cases with adverse prognosis [1].
CGH analysis demonstrated to be useful in distinguishing LMS from STUMP and in predicting
the clinical behaviour of the latest [56].
In summary, most molecular markers have been studied in relation to LMSs progression and
prognosis. However, large studies are still needed to validate their usefulness as possible
therapeutic targets.
5.12. Therapeutic approaches
5.12.1. Surgery
Hysterectomy with tumor debulking may be considered the treatment of choice in patients with
uterine LMS [1]. In postmenopausal women, hysterectomy and bilateral salpingo-oophorectomy
represent the gold standard. Ovarian preservation may be considered in premenopausal patients
with early stage LMS, limited to the uterus [57]. Patients without residual disease after surgical
resection would have an improved survival if compared with those undergoing suboptimal
surgical resection [57]. The role of lymph node dissection remains controversial, since lymphatic
metastases occur only in a small percentage of cases, frequently associated with intra-abdominal
disease. The incidence of retroperitoneal lymph node metastases is low in patients harboring a
uterine LMS. On the other side, nodal metastasis has been reported in 50% of women with an
LMS mass of 6–10 cm. This fact would suggest to also consider tumor size in planning surgical
management. Presently, among postmenopausal women harboring an LMS larger than 5 cm its
maximum diameter, lymph node dissection should be considered [57], although lymph nodes
metastases were identified in 6.6–11% of women undergoing lymphadenectomy [1, 57].
In patients with localized metastases, complete metastasectomy enhances disease-specific sur-
vival. Particularly, in patients with pulmonary metastasis, metastasectomy would bring to a 5-
year survival rate of 43–46.8%, with an overall 3-year disease-free survival rate of 27.8% [58].
As previously shown, since the vast majority of LMSs are diagnosed after surgery for a
suspected benign uterine mass, it would be extremely important to avoid uterine morcellation
or intraoperative rupture of the mass into the peritoneal cavity.
5.12.2. Adjuvant therapies
The role of postoperative adjuvant therapies remains controversial, since no study clearly
confirmed their benefits in the management of uterine LMSs. Radiation does not show a
significant impact on the overall survival, although it seems to have a role in controlling local
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disease, local recurrences and in palliation [59]. In general, CT with a single agent did not
demonstrate a significant improvement of the LMS outcome, with limited clinical benefits.
Moreover, only tumors with ER/PR receptors may respond to hormonal therapy [59]. Adju-
vant chemotherapy is not standardly administered in patients who underwent hysterectomy
for LMS confined to the uterus (stages I and II) [60]. The management of advanced uterine
LMS is now based on a first-line regimen including Doxorubicin/Doxorubicin plus Ifosfamide
[61]. The use of Gemcitabine or Gemcitabine plus Docetaxel produced conflicting results [61].
A French randomized study by Pautier et al. demonstrated a better 3- and 5-year disease-free
survival in patients with multiagent CT, in comparison with women receiving RT alone [62].
Conversely, the use of multiagent CT or the combination of CT and RT proved to be associated
with a significant increase in toxicity [62]. Trabectedin is a tetrahydroisoquinoline alkaloid.
Trabectedin interferes with several transcription factors, DNA-binding proteins and DNA
repair pathways, thus resulting in G2-M cell-cycle arrest and apoptosis [63, 64]. The two main
advantages to use Trabectedin would rely on (1) therapeutic benefits that can be maintained by
extending the use beyond six cycles and (2) reliable tolerability. All these findings would
underline the possible role of Trabectedin in the management of advanced/persistent/recurrent
LMS, although this drug has not been approved by the Food and Drug Administration yet
[65, 66]. Some authors reported the cytoreductive surgery with hyperthermic intraperitoneal
CT (CRS-HIPEC) as a promising treatment to achieve prolonged survival for peritoneal
spreading LMS [67]. In general, chemotherapic protocols do not lead to a clinically significant
response in high-grade LMS cases; on the other side, palliative CT is a rationale approach to
improve the quality of life in patients with advanced unresectable disease.
A trial by the European Organization for Research and Treatment of Cancer failed to demon-
strate some benefits of adjuvant RT in treating patients with LMS in stages I and II after surgery
[68, 69]. These data were also confirmed by SEER (Surveillance, Epidemiology, and End Results)
database [70]. On the other side, a retrospective study from Sanpath et al. demonstrated an
improved outcome in women receiving RT after surgery, in comparison with surgery alone [71].
Finally, a consensus by the Gynecologic Cancer InterGroup (GCIG) established that adjuvant RT
does not confer survival benefits to patients undergoing complete resection of uterus-limited
LMS. Moreover, in advanced or recurrent LMS, RT may only have a minor role [72].
5.13. Spread and metastases
Although LMS shows metastatic potential and a high rate of recurrence, patients usually
present with early stage of disease. If present, the extension of the LMSs outside the uterus
occurs into the pelvis. About 3% of LMS at stages I and II show lymph nodes involvement, as a
consequence of intraperitoneal spreading. A high proportion of patients without lymph nodes
involvement would develop distant metastasis, the favored site being lung, brain, liver and
bone. Direct extension to cervix and vagina is commonly observed [1].
5.14. Prognostic factors and survival
LMSs are often associated with a poor prognosis. A 5-year disease-specific survival is about
20–30%; a 5-year survival rate is 50–60% in stage I and 15% in more advanced stages. Death
frequently occurs within 2 years from diagnosis, although a long disease-free interval was
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described for low-stage LMS confined to the uterus [1]. In stage I, tumor size represents the
most important prognostic factors [20]. Age at presentation and mitotic index remain contro-
versial. In a large Norwegian report including 245 uterine LMSs confined to the uterus, tumor
size and mitotic rate demonstrated to be useful in stratifying patients in different prognostic
groups [73]. In truth, correlation between survival, patients’ age, clinical stage, tumor size, the
presence/absence of necrosis, mitotic rate, the degree of nuclear pleomorphism and vascular
invasion varies among the different studies. Presently, nuclear pleomorphism, high mitotic
rate, extensive tumor cell necrosis, vascular invasion, a size greater than 5 cm and non-spindle
morphology are considered negative prognostic factors in low-stage LMS [1]. Prognostic
significance of DNA ploidy and TP53 expression has been described, although confirmation
is still needed [74]. Ancillary parameters such as p53, p16, Ki67 and Bcl-2 have also been
explored, but results are still confusing. Recurrences are seen in 53–71% of the cases. All
patients with extra pelvic metastasis usually die within 6 years from diagnosis [1].
5.15. Future perspectives
The genetic heterogeneity of the uterine LMSs makes the identification of driver mutations and
therapeutic targets more difficult [75]. Recently, recurrent mutations of alpha thalassaemia/
mental retardation syndrome X-linked (ATRX) gene have been detected. Although ATRX
inhibitors might be considered as new possible therapeutic targets, their benefits are still to be
defined [76, 77]. Since MDM2 inhibitors have proven to be efficient in preclinical settings,
agents such as AMG232 and RG7112 are currently under investigation in a variety of cancer
types [78].
In summary, the standard treatment for both early and advanced uterine LMSs remains the
hysterectomy. In postmenopausal women, bilateral salpingo-oophorectomy and complete
cytoreduction of the tumor with adherent structures, even if not infiltrated, are
recommended. For uterus-limited disease (early stage), neoplastic mass should be removed
en bloc. Metastasectomy should be considered in patients with metastatic LMS. Adjuvant
RT and CT should not be considered in routine practice, especially in women in which
tumor has been completely removed. CT with a single agent (Doxorubicin, Gemcitabine
and Trabectedin) or in combination might be promising in patients with advanced, persis-
tent or recurrent LMS. Presently, many efforts are focused to define the molecular etiology
of LMS, in order to provide a better care for this highly lethal neoplasia.
5.16. Key points
• Uterine leiomyomas represent the most common gynecological benign neoplasia. Uterine
sarcoma is rare. The percentage of incidental LMS among women undergoing surgery for
suspected leiomyoma ranges from 0.2 to 1.7% and increases with age.
• Among women in reproductive age, a rapidly enlarging uterine mass should not be
suspected for LMS. A new or growing uterine mass in postmenopausal women needs
further evaluation.
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• Leiomyomas do not appear to progress to sarcoma, with the exception of some histolog-
ical variants.
• No pelvic imaging is undoubtedly able to distinguish between leiomyoma and LMS.
• It is not recommended to perform hysterectomy to exclude malignant neoplasm. Con-
versely, hysterectomy is suggested when the presence of LMS is strongly suspected by
MRI, in the presence of multiple risk factors or when thoracic imaging demonstrated lung
metastases.
• The influence of adjuvant therapy on survival is uncertain. RTmay be useful in controlling
local recurrences; CT with doxorubicin or docetaxel/gemcitabine should be considered as
the first-line choice in advanced or recurrent disease.
• Multidisciplinary evaluation of LMS is essential.
6. Uterine smooth muscle tumors of uncertain malignant potential
Uterine smooth muscle tumors, which cannot be unequivocally diagnosed as benign or malig-
nant, are designated as STUMPs [79]. STUMPs represent a heterogeneous group of neoplasia
with a borderline behaviour. Because of their rarity and the evolving knowledge about them,
the proper management of patient bearing STUMP represents a dilemma. The lack of uniform
diagnostic criteria may often result in STUMP over diagnosis. The term ‘STUMP’ was first
used by Kempson et al., in 1973 [80]. He clustered STUMPs into three groups, basing on
cytological atypia, tumor cell necrosis and mitosis (Figure 4A, B):
1. Atypical leiomyoma with a low risk of recurrence: diffuse moderate–severe atypia, <10
mitosis MFs/10 HPFs and no tumor cell necrosis.
2. Atypical leiomyoma with limited experience: focal moderate-severe atypia, <20 mitosis/10
HPFs and no tumor cell necrosis.
3. Smooth muscle tumor with a low malignant potential: absent-mild nuclear atypia, mitosis
less than 10/10 HPFs and the presence of tumor cell necrosis.
Later, Kempson et al. classified STUMPs as those tumor with a mitotic count major than 15
mitosis/10 HPFs [81, 82]. The largest study on uterine STUMP was done by Guntupalli et al.
[83], which grouped STUMPs into five categories:
Group 1: the presence of tumor cell necrosis, the absence of atypia, and mitotic count <10/10
HPFs.
Group 2: the absence of tumor cell necrosis, diffuse atypia and mitotic count <10/10 HPFs.
Group 3: the absence of tumor cell necrosis, the absence of atypia and mitotic count >20/10
HPFs.
Group 4: hypercellularity and mitotic count >4/10 HPFs.
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Group 5: irregular margins or vascular invasion at the periphery of the tumor.
Mitotically active leiomyoma, considered as benign variants of leiomyoma, differs from
STUMP due to the lacking of recurrences and metastases outside the pelvis [83]. On the
opposite side, the difference between LMS and STUMP would rely on the aggressive clinical
course, with early recurrence and metastases of the former, and on lower tumor growth and
possible delayed recurrence of the latter [83]. The clinical presentation of STUMPs resembles
signs and symptoms of uterine leiomyomas: rapidly growing pelvic mass, abnormal uterine
bleeding, pelvic pain and vaginal discharge. Risk factors are still unclear, as well as clinical
behaviour. The mean age at diagnosis is 45 years and the vast majority of patients are
premenopausal women [84].
6.1. Pathological findings
Recent studies characterized the natural history of smooth muscle neoplasms. Physiologically,
myometrial stem cells induce cells proliferation and tissue regeneration through strictly regu-
lated processes [85]. Uterine smooth muscle cells undergo multiple cycles of growth and
involution induced by oestrogens and progesterone stimulation. These cells also receive para-
crine signaling from stem cells, in order to regulate physiologic process [85]. Genetic mutations
and chromosomal rearrangements in myometrial stem cells would be induced by repeated
endocrine and paracrine stimulation [85]. Mutations and genetic rearrangements would cause
unregulated cells proliferation driving smooth muscle tissue towards a spectrum of neoplasia
ranging from leiomyomas to LMSs [86]. In particular, the deletion of the short arm of chromo-
some 1 (1p) has been associated with a possible malignant behaviour of myometrial cells [87].
Figure 4. Uterine smooth muscle tumor of uncertain malignant potential (STUMP). (A) Overview, EE, 4x. (B) Nuclear
atypia, EE, 20x. (C) p16 positive stain, 10x. (D) Smooth muscle actin positive stain, 10x.
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6.2. Diagnostic imaging
No reliable method is able to pre-operatively distinguish between benign and malignant
behaviour of STUMP. Although some MRI features may differentiate tissue intensity, these
elements are no specific. Similar to leiomyoma, STUMPs demonstrate homogeneous low
signal on T2-weighted images. On the other hand, STUMP and leiomyosarcoma often present
with areas of heterogeneous high T2 signal intensity. Recent data would suggest how the
combination of hypointense T1 signal, moderate T2 signal intensity and high signal intensity
on diffusion-weighted imaging (DWI) might be indicative of a leiomyoma variant or STUMP
[88]. The utility of positron emission tomography/computed tomography (PET/CT) is still to be
defined.
6.3. Immunohistochemistry
A panel of antibodies such as p16, p53, p21 and Ki-67/MIB1 may be helpful in distinguishing
STUMP from leiomyoma and LMS (Figure 4C) [1]. Ki-67/MIB1 and p53 expressions are
significantly higher in LMS if compared with STUMP. p16 shows a significant increased
expression starting from leiomyoma to LMS. Smooth muscle actin is positive in STUMP
(Figure 4D). A significant difference has been found in PR expression when comparing
STUMP and leiomyosarcoma. Bcl-2 is more frequently expressed in leiomyomas with respect
to STUMP and LMS. Finally, the expression of Bcl- 2 in STUMP is indicative of a good
prognosis [89].
6.4. Therapeutic approaches
6.4.1. Surgery
No standard protocols for the management of patients with suspected STUMP have been
defined. Present recommendations are based on guidelines for LMS. Considering the high risk
of recurrence, hysterectomy represents the gold standard for women completing their child-
bearing. Myomectomy followed by hysterectomy after childbearing.is suggested in patients
who desired maternity. Since STUMPs may show delayed recurrences, patients with surgically
removed STUMP should get CT of chest, abdomen and pelvis at baseline, followed by physical
examinations every 6 months for 5 years. When myomectomy is performed for fertility spar-
ing, US evaluation every 6 months, followed by yearly MRI and chest X-ray for 5 years have
been proposed [89].
6.4.2. Adjuvant therapies
The usefulness of adjuvant therapy for STUMP is not clear yet, since few studies have been
performed. In general, due to the low recurrence rate of these neoplasias, no role has been
suggested. If recurrence occurs, surgical excision of the mass is followed by adjuvant therapy,
such as pelvic RT. CT (with Doxorubicin and Cisplatin), Medroxyprogesterone or GnRH
should be performed [89]. In the presence of metastasis and in premenopausal patients, some
authors suggest achieving hormonal suppression to prevent STUMP progression [89].
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6.5. Prognosis
STUMP recurrences are observed in about 7% of the cases. The median of survival after
recurrence is higher in STUMP than in LMS. In truth, recurred STUMP should be biologically
considered as low-grade LMS, even if this diagnosis cannot be achieved until a recurrence
develops [90]. In this context, the number of mitosis seems to have the highest value in
predicting the clinical behaviour and the prognosis of STUMP [91]. STUMP metastases are
rare. They commonly occur in lungs, although the involvement of bones has also been
described [1].
In conclusion, the management of STUMPs remains controversial. In general, patients with
STUMP should be counseled regarding the potential risk of recurrence. Moreover, because of
the risk of metastases even many years after the initial diagnosis, patients with STUMP require
a long-term surveillance [92]. These considerations highlight the need of a multidisciplinary
approach, which includes gynecologists, gynecological pathologists and oncologists, to early
detect disease and to establish the correct management. Finally, the future research should put
the attention on the detection of an ideal biomarker, able to predict the outcome of STUMPS
and to personalize both surgical and oncological strategies.
6.6. Key points
• STUMPs represent a heterogeneous group of neoplasia and a gray area in diagnostic
pathology of uterine sarcomas.
• The vast majority of STUMPs demonstrated a benign behaviour, although follow-up with
adjuvant therapy is strongly recommended.
• Immunohistochemistry with Ki67/MIB1 and p53 antibodies may help stratify the progno-
sis.
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